| Clark J Fullmer Ii, DPM | |
|
2615 Fairway St, Dickinson, ND 58601 | |
| (701) 456-6000 | |
| Not Available |
| Full Name | Clark J Fullmer Ii |
|---|---|
| Gender | Male |
| Speciality | Podiatry |
| Experience | 29 Years |
| Location | 2615 Fairway St, Dickinson, North Dakota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1649240557 | NPI | - | NPPES |
| 14953 | Medicaid | ND |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 213ES0103X | Podiatrist - Foot & Ankle Surgery | 60 (North Dakota) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Chi St Alexius Health Dickinson | Dickinson, ND | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Omaha Therapy Inc | 1557270915 | 45 |
| Sanford Bismarck | 9739098575 | 448 |
News Archive
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, presented clinical data and analysis from its Phase 2a clinical trial of LX4211 for patients with type 2 diabetes mellitus at ENDO 2010 today. The results reported today included newly-obtained data showing a trend of increased total GLP-1 in both LX4211 treatment arms relative to placebo as measured in a post-trial analysis of blood samples.
Comprehensive Care Corporation, a leading behavioral health, substance abuse and pharmacy management provider for employers, Taft-Hartley health and welfare funds, and managed care companies, today announced that it has entered into an agreement with Upstate Financial Service/ John Argiro (collectively, "Mr. Argiro"), a leading consulting firm in healthcare to local and national unions, municipalities and private-sector groups.
Physicians who see patients with mitochondrial disease now have a practical new tool-a set of guidelines for managing and caring for those patients.
Debiopharm Group, the Swiss-based global biopharmaceutical company that focuses on the development of prescription drugs that target unmet medical needs including oncology, today announced the start of a phase I, open label multicenter study of a selective FGFR 1, 2, 3 inhibitor, Debio 1347 (CH5183284) in patients with advanced solid tumors.
› Verified 3 days ago
| Provider Name | Sanford Bismarck |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1811941172 PECOS PAC ID: 9739098575 Enrollment ID: O20031105000403 |
News Archive
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, presented clinical data and analysis from its Phase 2a clinical trial of LX4211 for patients with type 2 diabetes mellitus at ENDO 2010 today. The results reported today included newly-obtained data showing a trend of increased total GLP-1 in both LX4211 treatment arms relative to placebo as measured in a post-trial analysis of blood samples.
Comprehensive Care Corporation, a leading behavioral health, substance abuse and pharmacy management provider for employers, Taft-Hartley health and welfare funds, and managed care companies, today announced that it has entered into an agreement with Upstate Financial Service/ John Argiro (collectively, "Mr. Argiro"), a leading consulting firm in healthcare to local and national unions, municipalities and private-sector groups.
Physicians who see patients with mitochondrial disease now have a practical new tool-a set of guidelines for managing and caring for those patients.
Debiopharm Group, the Swiss-based global biopharmaceutical company that focuses on the development of prescription drugs that target unmet medical needs including oncology, today announced the start of a phase I, open label multicenter study of a selective FGFR 1, 2, 3 inhibitor, Debio 1347 (CH5183284) in patients with advanced solid tumors.
› Verified 3 days ago
| Provider Name | Sanford Bismarck |
|---|---|
| Provider Type | Part B Supplier - Ambulatory Surgical Center |
| Provider Identifiers | NPI Number: 1598185597 PECOS PAC ID: 9739098575 Enrollment ID: O20040304000249 |
News Archive
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, presented clinical data and analysis from its Phase 2a clinical trial of LX4211 for patients with type 2 diabetes mellitus at ENDO 2010 today. The results reported today included newly-obtained data showing a trend of increased total GLP-1 in both LX4211 treatment arms relative to placebo as measured in a post-trial analysis of blood samples.
Comprehensive Care Corporation, a leading behavioral health, substance abuse and pharmacy management provider for employers, Taft-Hartley health and welfare funds, and managed care companies, today announced that it has entered into an agreement with Upstate Financial Service/ John Argiro (collectively, "Mr. Argiro"), a leading consulting firm in healthcare to local and national unions, municipalities and private-sector groups.
Physicians who see patients with mitochondrial disease now have a practical new tool-a set of guidelines for managing and caring for those patients.
Debiopharm Group, the Swiss-based global biopharmaceutical company that focuses on the development of prescription drugs that target unmet medical needs including oncology, today announced the start of a phase I, open label multicenter study of a selective FGFR 1, 2, 3 inhibitor, Debio 1347 (CH5183284) in patients with advanced solid tumors.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Clark J Fullmer Ii, DPM 2615 Fairway St, Dickinson, ND 58601-2590 Ph: (701) 456-6000 | Clark J Fullmer Ii, DPM 2615 Fairway St, Dickinson, ND 58601 Ph: (701) 456-6000 |
News Archive
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, presented clinical data and analysis from its Phase 2a clinical trial of LX4211 for patients with type 2 diabetes mellitus at ENDO 2010 today. The results reported today included newly-obtained data showing a trend of increased total GLP-1 in both LX4211 treatment arms relative to placebo as measured in a post-trial analysis of blood samples.
Comprehensive Care Corporation, a leading behavioral health, substance abuse and pharmacy management provider for employers, Taft-Hartley health and welfare funds, and managed care companies, today announced that it has entered into an agreement with Upstate Financial Service/ John Argiro (collectively, "Mr. Argiro"), a leading consulting firm in healthcare to local and national unions, municipalities and private-sector groups.
Physicians who see patients with mitochondrial disease now have a practical new tool-a set of guidelines for managing and caring for those patients.
Debiopharm Group, the Swiss-based global biopharmaceutical company that focuses on the development of prescription drugs that target unmet medical needs including oncology, today announced the start of a phase I, open label multicenter study of a selective FGFR 1, 2, 3 inhibitor, Debio 1347 (CH5183284) in patients with advanced solid tumors.
› Verified 3 days ago
Dr. Cherian Mathew, D.P.M. Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 2215 Sims St, Dickinson, ND 58601 Phone: 701-483-6986 Fax: 701-483-6974 |